{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:10:28Z","timestamp":1788786628159,"version":"build-2803163510"},"reference-count":35,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["ID#56272553"],"award-info":[{"award-number":["ID#56272553"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CSA-SI\/0004\/2015"],"award-info":[{"award-number":["NMRC\/CSA-SI\/0004\/2015"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Oestrogen receptor positive, human epidermal growth factor receptor-2 (HER2) negative breast cancer (BC) is the most frequently diagnosed BC subtype. Combinations of cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i) with anti-oestrogen therapy have led to improved survival compared with anti-oestrogen therapy alone for advanced\/metastatic BC. The evaluation of CDK4\/6i in the real-world facilitates treatment planning, insights into the incidence of drug toxicities, dose modifications including dose delays (DDs) and dose reductions (DRs) and improves prognostic accuracy in subgroups, for example geriatric patients, who are under-represented in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This multi-centre study analysed retrospective and prospective data from 456 patients treated with CDK4\/6i between January 2015 and December 2020. We examined patient characteristics, variation in prescribing practices, efficacy and toxicity outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In all, 456 patients were included in this study. The median age was 59 (range: 24\u201392). In total, 85 (19%) were \u2a7e70\u2009years old. In all, 122 (27%) and 119 (26%) of patients were treated in the first-line and second-line settings, respectively. In total, 25 (5%), 31 (7%) and 145 (32%) of patients had brain, peritoneum and liver metastasis, respectively, at the time of CDK4\/6i initiation. On univariate analysis, heavily pre-treated patients and those with distant metastases, involving the liver, brain or peritoneum, had significantly shorter progression-free survival (PFS) and 24-month overall survival (OS). Elderly patients (\u2a7e70) had a shorter PFS; OS results were not mature. Majority of patients ( n\u2009=\u2009362, 80%) initiated treatment with the United States FDA-approved starting dose of CDK4\/6i. In all, 330 (72%) had at least one DD and 217 (48%) patients required at least one DR, but these dose modifications were not associated with poorer survival outcomes. Patients age \u2a7e70 were more likely to require dose modifications leading to a lower treatment dose. The most common reason for DD\/DR was neutropenia (60%) and the incidence of febrile neutropenia was only 2%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our study indicates CDK4\/6i is effective and safe. Age\u2009\u2a7e\u200970, distant metastases to liver, peritoneal or brain were negative prognostic factors. Age\u2009\u2a7e\u200970 was associated with significantly increased requirement for dose modification; however, this did not impact survival outcomes. These findings provide reassurance that survival outcomes are not adversely affected in elderly patients when DD\/DR is indicated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359221139678","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T02:24:14Z","timestamp":1671416654000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["Real-world outcomes from use of CDK4\/6 inhibitors in the management of advanced\/metastatic breast cancer in Asia"],"prefix":"10.1177","volume":"14","author":[{"given":"Jia Li","family":"Low","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, National Cancer Center Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavina","family":"Bharwani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmen","family":"Wong","sequence":"additional","affiliation":[{"name":"Icon Cancer Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ow","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Eng","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Choo","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joline","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert John","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Muthu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ngoi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqin","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sing Huang","family":"Tan","sequence":"additional","affiliation":[{"name":"OncoCare Cancer Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Chin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute (NCIS), 1E Lower Kent Ridge Road, Singapore 119228"},{"name":"Cancer Science Institute, Singapore"},{"name":"Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,12,18]]},"reference":[{"key":"bibr1-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937"},{"key":"bibr2-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017728928"},{"key":"bibr3-17588359221139678","first-page":"688","volume":"26","author":"Lim E","year":"2012","journal-title":"Oncology (Williston Park, N.Y.)"},{"key":"bibr4-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.010"},{"key":"bibr5-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.01.006"},{"key":"bibr6-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0661-5"},{"key":"bibr7-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"bibr8-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4518-8"},{"key":"bibr9-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"bibr10-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765"},{"key":"bibr11-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0097-z"},{"key":"bibr12-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810527"},{"key":"bibr13-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"bibr14-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"bibr15-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.353"},{"key":"bibr16-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"bibr17-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0754"},{"key":"bibr18-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270"},{"key":"bibr19-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-020-01193-z"},{"key":"bibr20-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01409-8"},{"key":"bibr21-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e13028"},{"key":"bibr22-17588359221139678","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000774","volume":"5","author":"Fountzilas E","year":"2020","journal-title":"ESMO Open"},{"key":"bibr23-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920987651"},{"key":"bibr24-17588359221139678","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1264"},{"key":"bibr25-17588359221139678","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2020.04.1534","volume":"23","author":"Harbeck N","year":"2020","journal-title":"Value Health"},{"key":"bibr26-17588359221139678","volume":"32","author":"Xu B","year":"2021","journal-title":"Ann Oncol"},{"key":"bibr27-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-P6-18-21"},{"key":"bibr28-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4523-y"},{"key":"bibr29-17588359221139678","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2018.36.15_suppl.1060","volume":"36","author":"Verma S","year":"2018","journal-title":"J Clin Oncol"},{"key":"bibr30-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01263-0"},{"key":"bibr31-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.263"},{"key":"bibr32-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1517\/17425250902800153"},{"key":"bibr33-17588359221139678","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.08.63"},{"key":"bibr34-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31822722b6"},{"key":"bibr35-17588359221139678","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0344"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359221139678","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359221139678","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359221139678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:27:56Z","timestamp":1777588076000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359221139678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":35,"alternative-id":["10.1177\/17588359221139678"],"URL":"https:\/\/doi.org\/10.1177\/17588359221139678","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"17588359221139678"}}